Athersys to Present at BIO CEO & Investor Conference

        Print
| Source: Athersys, Inc.

CLEVELAND, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that the Company will present at the 2014 BIO CEO & Investor Conference to be held at the Waldorf Astoria from February 10-11, 2014 in New York City.

Dr. Gil Van Bokkelen, Chairman and Chief Executive Officer, will present on Tuesday, February 11, 2014 at 2:00 p.m. Eastern Standard Time.

The BIO CEO & Investor Conference assembles a select group of established biotech companies, as well as top public and private equity investors and members of the sell-side investment community, to explore the current investment landscape and opportunities in life sciences. In addition to plenary sessions and panel discussions on timely business topics and key therapeutic areas, the conference features presentations by over 130 leading biotechnology and pharmaceutical companies, as well as a number of nonprofit and venture philanthropy organizations.

To listen to the live audio webcast of the presentation during the event, please visit: www.athersys.com. A replay of the webcast will be available for 30 days after the initial presentation.

About Athersys

Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft-versus-host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products.

William (B.J.) Lehmann, J.D.
President and Chief Operating Officer
Tel: (216) 431-9900


Investor Relations:
Lisa M. Wilson
In-Site Communications
Tel: (917) 543-9932